Scripps Research Institute and Aileron Therapeutics™ Enter Exclusive Worldwide Agreement to Utilize "Click" Chemistry for the Development of Stabilized Peptide and Protein Therapeutics

LA JOLLA, Calif. & CAMBRIDGE, Mass.--()--The Scripps Research Institute and Aileron Therapeutics™ today announced that they have entered into an agreement that will add Scripps Research’s “Click” chemistry to Aileron’s proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide™ technology. The agreement provides Aileron exclusive worldwide rights to utilize Click chemistry for therapeutics and non-exclusive worldwide rights for diagnostics with Aileron’s stabilized peptide and protein technology platforms. The novel Click chemistries subject to this agreement were developed by Nobel Laureate K. Barry Sharpless, Ph.D., the W.M. Keck Professor of Chemistry at Scripps Research.

Aileron’s Stapled Peptide™ technology is a breakthrough solution to drug potentially thousands of as-yet intractable disease targets, including those originating from long sought-after intracellular protein-protein interactions. The relationship with Scripps Research and the acquisition of this groundbreaking “Click” chemistry patent estate further establishes Aileron as the global leader in stabilized peptides and proteins.

“Aileron has discovered how to enable, and more importantly where to use, certain peptide and protein macrocyclization chemistries to drive therapeutic product profiles,” said Tomi Sawyer, Ph.D., Chief Scientific Officer and Senior VP of Drug Discovery and Innovative Technologies at Aileron. “This agreement with Scripps Research further expands our arsenal to create novel therapeutics, including protein and non-helical peptide therapeutics, and will give us access to one of the top biomedical research organizations in the world.”

About Click Chemistry

Click chemistry describes synthetic chemistry tailored to generate substances quickly and reliably by joining (“clicking”) small reactive molecular building blocks together selectively and covalently to drive a spontaneous and irreversible binding reaction, a process that is inspired by natural chemistry. This approach may effectively accelerate the drug discovery process by utilizing a few practical and reliable reactions, and by making each reaction in a multistep synthesis fast, efficient and predictable.

About Stapled Peptide™ Technology

Aileron’s proprietary Stapled Peptide™ technology platform “locks” peptides into their biologically active shape by the formation of one or more stabilizing macrocycles, mimicking the structures found in nature. This process captures the best features of both small molecules and therapeutic proteins, ultimately endowing the peptide with unique and beneficial drug-like properties, including efficient cell penetration, improved pharmacokinetics, high-affinity binding to large target protein surfaces and excellent stability within the body. This unique combination of features will greatly expand the number of "druggable" therapeutic targets by providing a unique opportunity to address the thousands of intracellular protein-protein interactions that remain a challenge for functional modulation by current therapeutics. In preclinical studies, Aileron’s Stapled Peptide™ compounds have been shown to possess compelling potency, in vivo stability and cell permeability.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, Scripps Research currently employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Headquartered in La Jolla, California, the institute also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is located in Jupiter, Florida. For more information, see www.scripps.edu

About Aileron Therapeutics™

Headquartered in Cambridge, Massachusetts, Aileron Therapeutics™ is a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptide™ therapeutics. The Stapled Peptide™ technology is a breakthrough solution to address thousands of therapeutically important yet currently undruggable targets. Stapled Peptide™ compounds have demonstrated their unique ability to penetrate cells throughout the body and modulate protein-protein interactions, critical control points for most human diseases. Founded in 2005 and supported by funding from a leading syndicate of investors, Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases. For more information, see www.aileronrx.com

Contacts

Aileron Therapeutics:
Steven Kafka, Ph.D., +1 617-995-2816
Chief Financial Officer, VP Finance & Operations
or
Media for Aileron Therapeutics:
MacDougall Biomedical Communications
Kari Watson or Jennifer Conrad, +1 781-235-3060
or
Media for The Scripps Research Institute:
Mika Ono, +1 858-784-2052

Release Summary

The Scripps Research Institute and Aileron Therapeutics today announced that they have entered into an agreement that will add Scripps Research’s Click chemistry to Aileron’s proprietary platforms.

Sharing

Contacts

Aileron Therapeutics:
Steven Kafka, Ph.D., +1 617-995-2816
Chief Financial Officer, VP Finance & Operations
or
Media for Aileron Therapeutics:
MacDougall Biomedical Communications
Kari Watson or Jennifer Conrad, +1 781-235-3060
or
Media for The Scripps Research Institute:
Mika Ono, +1 858-784-2052